MedTrace Logo

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

NCT01560143 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-02-09

Study results available
· View outcomes & findings →

Summary

If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without regard to weight.

Conditions

Interventions

DRUG

Tigecycline

100 mg IV as a single infusion over 30 minutes

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Manjunath Prakash Pai

    lead OTHER

Principal Investigators

  • Manjunath P Pai, PharmD · University of Michigan

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01560143 on ClinicalTrials.gov